Stanford scientists have identified tuberculosis (TB) epitopes preferentially recognized by T cells in patients who naturally resist or control TB infection. Targeting these epitopes for vaccine development could lead to effective vaccines for TB.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford scientists have developed broadly neutralizing antibodies against sarbecoviruses , including SARS-CoV-2 related Clade 1b, SARS-CoV related Clade 1a and Clade 3 viruses, paving the way for future vaccines and therapeutics.
Stanford researchers have developed saponin lipid-based nanoparticles in which both toll-like receptor agonists (TLRas) and other potent molecular adjuvants can be encapsulated to improve vaccine potency, increase antibody titers, and induce more robust neutralizing antibody r
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Stanford researchers have developed a multi-omics method for predicting the strength and durability of immune responses to vaccines shortly after vaccination. The COVID-19 pandemic was a grave demonstration of the threat pandemics pose to global public health.